Shuttle Pharmaceuticals Stock (NASDAQ:SHPH)

Revenue Ownership Financials Chart

Previous Close

$0.68

52W Range

$0.58 - $4.94

50D Avg

$1.07

200D Avg

$2.44

Market Cap

$2.35M

Avg Vol (3M)

$1.11M

Beta

0.74

Div Yield

-

SHPH Company Profile

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Aug 31, 2022

Website

SHPH Performance

SHPH Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-5.89M	$-2.55M	$-1.74M
Net Income	$-6.59M	$-3.10M	$-1.20M
EBITDA	$-5.89M	$-2.16M	$-1.68M
Basic EPS	$-0.44	$-0.30	$-0.09
Diluted EPS	$-0.44	$-0.30	$-0.09

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
TLRY	Tilray Brands, Inc.
DERM	Journey Medical Corporation
AKAN	Akanda Corp.
LFCR	Lifecore Biomedical, Inc.
ORGO	Organogenesis Holdings Inc.
CTLT	Catalent, Inc.